Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...

Use of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among ...

With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but ...

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. | One of Merck KGaA’s leading immunology ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

Merck MRK stock has declined 7.8% in the past month — in roughly the span after it announced fourth-quarter 2024 results and ...

The Orphan Drugs Market is experiencing significant growth due to increasing investment in rare disease research, regulatory incentives, and advancements in biotechnology. Orphan drugs are specialized ...

Researchers conduct a retrospective, population-based cohort study of adult patients with metastatic breast cancer who underwent genomic profiling at academic institutions.

when Merck entered into an agreement with Daiichi Sankyo (OTCPK:DSKYF) to develop several antibody-drug conjugates. For comparison, and using Seeking Alpha data, Merck's non-GAAP EPS is expected ...